Pancreatic enlargement in a patient receiving therapy with vasodilators for pulmonary arterial hypertension: a case report

Someya, Yuko; Koyasu, Sho; Ohnishi, Y.; Ohno, Tsuyoshi; Shimizu, Hironori; Isoda, Hiroyoshi; Nakamoto, Yuji

doi:10.1007/s00261-022-03458-9

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is a valuable therapeutic option for severe pulmonary arterial hypertension (PAH) [ 33 ]. While thyroid enlargement is a well-known adverse effect in some PAH patients treated by epoprostenol, reports of pancreatic enlargement following epoprostenol therapy are limited [ 34 ] (Fig. 13 ).…”

Section: Introductionmentioning

confidence: 99%

Key CT and MRI findings of drug-associated hepatobiliary and pancreatic disorders

Ichikawa,

Goshima

2023

Jpn J Radiol

View full text Add to dashboard Cite

Obtaining an imaging diagnosis of various hepatobiliary and pancreatic disorders caused by certain drugs can often be challenging. Familiarity with these conditions may improve diagnostic accuracy and patient management. This review aimed to describe the imaging findings of drug-associated hepatobiliary and pancreatic disorders and identify suggestions for obtaining a correct diagnosis. We focused on relatively common disorders or those that can present with characteristic imaging findings, such as drug-induced acute hepatitis, sinusoidal obstruction syndrome, focal nodular hyperplasia-like lesions, hepatocellular adenoma, pseudocirrhosis, chemotherapy-associated steatohepatitis, amiodarone deposition in the liver, secondary iron overload, drug-induced pancreatitis, pancreatic enlargement after epoprostenol therapy, ceftriaxone-associated gallbladder pseudolithiasis, immune-related adverse events, and methotrexate-associated lymphoproliferative disorders.

show abstract

Section: Introductionmentioning

confidence: 99%